CureVac NV
http://www.curevac.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From CureVac NV
GSK Still Waiting For Infectious Disease Strategy To Move The Needle
Ongoing Zantac litigation continues to cloud GSK’s share price, but it hopes a stream of infectious disease readouts will sway investor sentiment as it prepares for Arexvy’s launch.
GSK’s Walmsley On US v. EU COVID-Flu Combos, RSV Branding, And Investing In Infectious Disease
COVID vaccine makers already licensed in the US will have a leg up on in the combination respiratory vaccine space since aspiring new entrants like GSK will have to do efficacy work to get FDA approval. CEO Walmsley offers insight into the company’s vaccine strategy.
Scrip Asks…What Does 2023 Hold For Biopharma? Part 8: Therapeutic Area Advances
Neuroscience and oncology fuel high hopes for therapeutic R&D progress among 90-plus surveyed biopharma industry leaders.
Finance Watch: Aileron, Talaris, Frequency And The Search For Strategic Alternatives
Public Company Edition: Aileron, Talaris and Frequency said they will reduce expenses and seek options for maximizing shareholder returns under tough stock market conditions. However, CureVac and Supernus are among firms recently able to access new cash – $250m and $150m, respectively.
Company Information
- Industry
-
Pharmaceuticals
- Drug Delivery
- Vaccines
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
-
Drug Discovery Technologies
- Genomics-Proteomics
- Other Names / Subsidiaries
-
- CureVac GmbH
- CureVac BV
- Frame Therapeutics
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice